BioCentury | Oct 1, 2012
Finance

4Q Financial Markets Preview: Bellwether's ball

...Inc. 7/11/11 Up to $46M Mkt (drug) LipoScience Inc. 6/23/11 Up to $86.3M Mkt (diagnostic) IASO Pharma Inc....
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Avoiding burnout

...Up to $86.3M Mkt (diagnostic) Taiwan Liposome Co. Ltd. (Taiwan) (D) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Apr 23, 2012
Company News

Rib-X management update

...chief development officer, a newly created position, effective April 30, formerly president and CEO of Iaso Pharma Inc. WIR...
BioCentury | Apr 2, 2012
Finance

Some like it hot

...12/23/10 Up to $100M Registration Taiwan Liposome Co. Ltd. (Taiwan) (C) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...12/23/10 Up to $100M Registration Taiwan Liposome Co. Ltd. (Taiwan) (B) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Nov 14, 2011
Regulation

Inching toward feasibility

...Co. Ltd. Nemonoxacin Topoisomerase IV inhibitor Ph II completed Dong Wha Pharmaceutical Industrial Co. Ltd. (KSE:000020)/Iaso Pharma Inc....
BioCentury | Oct 3, 2011
Finance

Cost averaging down

...Co. Ltd. (Taiwan) 9/27/10 TBD Mkt (drug) Cutanea Life Sciences Inc. 8/12/10 $15M Ph II IASO Pharma Inc....
BioCentury | Jul 4, 2011
Financial News

Iaso Pharma amends IPO

Iaso Pharma Inc. , San Diego, Calif. Business: Infectious Date announced: 6/17/11 Type: IPO To be raised: Up to $25 million Shares: TBD Price: TBD Underwriter: Ladenburg Thalmann Note: IASO amended its IPO and dropped underwriters...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...Sciences Inc. 8/12/10 $15M Ph II Horizon Pharma Inc. 8/3/10 Up to $86.3M Mkt (drug) IASO Pharma Inc....
BioCentury | Apr 4, 2011
Finance

Hoping for a Springboard

...Sciences Inc. 8/13/10 $15M Ph II Horizon Pharma Inc. 8/3/10 Up to $86.3M Mkt (drug) IASO Pharma Inc....
Items per page:
1 - 10 of 21
BioCentury | Oct 1, 2012
Finance

4Q Financial Markets Preview: Bellwether's ball

...Inc. 7/11/11 Up to $46M Mkt (drug) LipoScience Inc. 6/23/11 Up to $86.3M Mkt (diagnostic) IASO Pharma Inc....
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Avoiding burnout

...Up to $86.3M Mkt (diagnostic) Taiwan Liposome Co. Ltd. (Taiwan) (D) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Apr 23, 2012
Company News

Rib-X management update

...chief development officer, a newly created position, effective April 30, formerly president and CEO of Iaso Pharma Inc. WIR...
BioCentury | Apr 2, 2012
Finance

Some like it hot

...12/23/10 Up to $100M Registration Taiwan Liposome Co. Ltd. (Taiwan) (C) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...12/23/10 Up to $100M Registration Taiwan Liposome Co. Ltd. (Taiwan) (B) 9/27/10 TBD Mkt (drug) IASO Pharma Inc....
BioCentury | Nov 14, 2011
Regulation

Inching toward feasibility

...Co. Ltd. Nemonoxacin Topoisomerase IV inhibitor Ph II completed Dong Wha Pharmaceutical Industrial Co. Ltd. (KSE:000020)/Iaso Pharma Inc....
BioCentury | Oct 3, 2011
Finance

Cost averaging down

...Co. Ltd. (Taiwan) 9/27/10 TBD Mkt (drug) Cutanea Life Sciences Inc. 8/12/10 $15M Ph II IASO Pharma Inc....
BioCentury | Jul 4, 2011
Financial News

Iaso Pharma amends IPO

Iaso Pharma Inc. , San Diego, Calif. Business: Infectious Date announced: 6/17/11 Type: IPO To be raised: Up to $25 million Shares: TBD Price: TBD Underwriter: Ladenburg Thalmann Note: IASO amended its IPO and dropped underwriters...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...Sciences Inc. 8/12/10 $15M Ph II Horizon Pharma Inc. 8/3/10 Up to $86.3M Mkt (drug) IASO Pharma Inc....
BioCentury | Apr 4, 2011
Finance

Hoping for a Springboard

...Sciences Inc. 8/13/10 $15M Ph II Horizon Pharma Inc. 8/3/10 Up to $86.3M Mkt (drug) IASO Pharma Inc....
Items per page:
1 - 10 of 21